Covance (CVD) Stock Price, News & Analysis

Company Overview

Covance Inc. is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services. The early development services include lead optimization services, preclinical services and clinical pharmacology services. The late-stage development services include central laboratory, Phase II-IV clinical development, and market access services.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CVD Stock Analysis - Frequently Asked Questions

How were Covance's earnings last quarter?

Covance Inc (NYSE:CVD) issued its quarterly earnings results on Wednesday, February, 4th. The healthcare company reported $0.97 earnings per share for the quarter, meeting analysts' consensus estimates of $0.97. The healthcare company earned $634 million during the quarter, compared to analysts' expectations of $631.30 million.

What other stocks do shareholders of Covance own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Covance investors own include Allena Pharmaceuticals (ALNA), Labcorp (LH), Arbutus Biopharma (ABUS), Ampliphi Biosciences (APHB), Asterias Biotherapeutics (AST), Can-Fite BioPharma (CANF) and Crescent Biopharma (CBIO).

Company Calendar

• Last Earnings: 2/04/2015
• Today: 10/10/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: N/A
• Industry: N/A
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NYSE:CVD
• CIK: 1023131
• Web: www.covance.com
• Phone: +1-609-4524440
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A